Unclassified white matter disorders: A diagnostic journey requiring close collaboration between clinical and laboratory services

C. A. Stutterd, A. Vanderver, P. J. Lockhart, G. Helman, K. Pope, E. Uebergang, C. Love, M. B. Delatycki, D. Thorburn, M. T. Mackay, H. Peters, A. J. Kornberg, C. Patel, V. Rodriguez-Casero, M. Waak, J. Silberstein, A. Sinclair, M. Nolan, M. Field, M. R. DavisM. Fahey, I. E. Scheffer, J. L. Freeman, N. I. Wolf, R. J. Taft, M. S. van der Knaap, C. Simons, R. J. Leventer

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Background: Next generation sequencing studies have revealed an ever-increasing number of causes for genetic disorders of central nervous system white matter. A substantial number of disorders are identifiable from their specific pattern of biochemical and/or imaging findings for which single gene testing may be indicated. Beyond this group, the causes of genetic white matter disorders are unclear and a broader approach to genomic testing is recommended. Aim: This study aimed to identify the genetic causes for a group of individuals with unclassified white matter disorders with suspected genetic aetiology and highlight the investigations required when the initial testing is non-diagnostic. Methods: Twenty-six individuals from 22 families with unclassified white matter disorders underwent deep phenotyping and genome sequencing performed on trio, or larger, family groups. Functional studies and transcriptomics were used to resolve variants of uncertain significance with potential clinical relevance. Results: Causative or candidate variants were identified in 15/22 (68.2%) families. Six of the 15 implicated genes had been previously associated with white matter disease (COL4A1, NDUFV1, SLC17A5, TUBB4A, BOLA3, DARS2). Patients with variants in the latter two presented with an atypical phenotype. The other nine genes had not been specifically associated with white matter disease at the time of diagnosis and included genes associated with monogenic syndromes, developmental disorders, and developmental and epileptic encephalopathies (STAG2, LSS, FIG4, GLS, PMPCA, SPTBN1, AGO2, SCN2A, SCN8A). Consequently, only 46% of the diagnoses would have been made via a current leukodystrophy gene panel test. Discussion: These results confirm the importance of broad genomic testing for patients with white matter disorders. The high diagnostic yield reflects the integration of deep phenotyping, whole genome sequencing, trio analysis, functional studies, and transcriptomic analyses. Conclusions: Genetic white matter disorders are genetically and phenotypically heterogeneous. Deep phenotyping together with a range of genomic technologies underpin the identification of causes of unclassified white matter disease. A molecular diagnosis is essential for prognostication, appropriate management, and accurate reproductive counseling.
Original languageEnglish
Article number104551
Pages (from-to)1-9
Number of pages9
JournalEuropean journal of medical genetics
Volume65
Issue number9
Early online date5 Jul 2022
DOIs
Publication statusPublished - 1 Sept 2022

Keywords

  • Brain diseases
  • Genetic testing
  • Genomics
  • High-throughput nucleotide sequencing
  • Phenotype

Cite this